Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry
- 26 May 2005
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (21) , 2202-2210
- https://doi.org/10.1056/nejmsa044115
Abstract
Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the legal agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators' control over trials.Keywords
This publication has 11 references indexed in Scilit:
- Failing the Public Health — Rofecoxib, Merck, and the FDANew England Journal of Medicine, 2004
- Clinical-Trial Agreements between Medical Schools and IndustryNew England Journal of Medicine, 2003
- Collaborating with Industry — Choices for the Academic Medical CenterNew England Journal of Medicine, 2002
- Academic Freedom in Clinical ResearchNew England Journal of Medicine, 2002
- A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry SponsorsNew England Journal of Medicine, 2002
- Institutions, Contracts, and Academic FreedomNew England Journal of Medicine, 2002
- Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 × 106/L CD4 Cell CountsA Randomized Controlled TrialPublished by American Medical Association (AMA) ,2000
- Uneasy Alliance — Clinical Investigators and the Pharmaceutical IndustryNew England Journal of Medicine, 2000
- Thyroid stormPublished by American Medical Association (AMA) ,1997
- A wilcoxon‐type test for trendStatistics in Medicine, 1985